Login to Your Account



$220M in Milestones per Target

Conjugate Reverb: Abbott Pays $25M to Broaden SeaGen Deal

By Randy Osborne
Staff Writer

Wednesday, October 24, 2012
Despite sales of its approved antibody-drug conjugate (ADC) Adcetris at levels described by analysts as "flat," Seattle Genetics Inc. scored an expansion of the deal begun last year with Abbott. The arrangement brings $25 million up front in exchange for Abbott's right to use the auristatin-based ADC technology against more targets than before.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription